The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

"FDA and EMA release collaborative AI framework for drug development" was originally created and published by Pharmaceutical ...

The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...

The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the world’s largest ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...

FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.

EMA and FDA define ten principles for AI use in medicines – in response to growing pressure from the industry.

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...